• Je něco špatně v tomto záznamu ?

Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey

J. Bronsky, L. de Ridder, FM. Ruemmele, A. Griffiths, S. Buderus, O. Hradsky, AC. Hauer,

. 2019 ; 68 (5) : 676-683. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025881

OBJECTIVES: Despite existence of international guidelines for diagnosis and management of inflammatory bowel diseases (IBD) in children, there might be differences in the clinical approach. METHODS: A survey on clinical practice in paediatric IBD was performed among members of the ESPGHAN Porto IBD working group and interest group, PIBD-NET, and IBD networks in Canada and German-speaking countries (CIDsCANN, GPGE), using a web-based questionnaire. Responses to 63 questions from 106 paediatric IBD centres were collected. RESULTS: Eighty-four percentage of centres reported to fulfil the revised Porto criteria in the majority of patients. In luminal Crohn disease (CD), exclusive enteral nutrition is used as a first-line induction therapy and immunomodulators (IMM) are used since diagnosis in the majority of patients. Infliximab (IFX) is mostly considered as first-line biological. Sixty percentage of centres have experience with vedolizumab and/or ustekinumab and 40% use biosimilars. In the majority of ulcerative colitis (UC) patients 5-aminosalicylates are continued as concomitant therapy to IMM (usually azathioprine [AZA]/6-MP). After ileocaecal resection (ICR) in CD patients without postoperative residual disease, AZA monotherapy is the preferred treatment. CONCLUSIONS: A majority of centres follows both the Porto diagnostic criteria as well as paediatric (ESPGHAN/ECCO) guidelines on medical and surgical IBD management. This reflects the value of international societal guidelines. However, potentially desirable answers might have been given instead of what is true daily practice, and the most highly motivated people might have answered, leading to some bias.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025881
003      
CZ-PrNML
005      
20201222155521.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MPG.0000000000002233 $2 doi
035    __
$a (PubMed)30664566
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bronsky, Jiri $u Department of Paediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
245    10
$a Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey / $c J. Bronsky, L. de Ridder, FM. Ruemmele, A. Griffiths, S. Buderus, O. Hradsky, AC. Hauer,
520    9_
$a OBJECTIVES: Despite existence of international guidelines for diagnosis and management of inflammatory bowel diseases (IBD) in children, there might be differences in the clinical approach. METHODS: A survey on clinical practice in paediatric IBD was performed among members of the ESPGHAN Porto IBD working group and interest group, PIBD-NET, and IBD networks in Canada and German-speaking countries (CIDsCANN, GPGE), using a web-based questionnaire. Responses to 63 questions from 106 paediatric IBD centres were collected. RESULTS: Eighty-four percentage of centres reported to fulfil the revised Porto criteria in the majority of patients. In luminal Crohn disease (CD), exclusive enteral nutrition is used as a first-line induction therapy and immunomodulators (IMM) are used since diagnosis in the majority of patients. Infliximab (IFX) is mostly considered as first-line biological. Sixty percentage of centres have experience with vedolizumab and/or ustekinumab and 40% use biosimilars. In the majority of ulcerative colitis (UC) patients 5-aminosalicylates are continued as concomitant therapy to IMM (usually azathioprine [AZA]/6-MP). After ileocaecal resection (ICR) in CD patients without postoperative residual disease, AZA monotherapy is the preferred treatment. CONCLUSIONS: A majority of centres follows both the Porto diagnostic criteria as well as paediatric (ESPGHAN/ECCO) guidelines on medical and surgical IBD management. This reflects the value of international societal guidelines. However, potentially desirable answers might have been given instead of what is true daily practice, and the most highly motivated people might have answered, leading to some bias.
650    _2
$a mladiství $7 D000293
650    _2
$a biosimilární léčivé přípravky $x terapeutické užití $7 D059451
650    _2
$a dítě $7 D002648
650    _2
$a ulcerózní kolitida $x diagnóza $x terapie $7 D003093
650    _2
$a Crohnova nemoc $x diagnóza $x terapie $7 D003424
650    _2
$a chirurgie trávicího traktu $x metody $x normy $x statistika a číselné údaje $7 D013505
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastroenterologie $x metody $x normy $x statistika a číselné údaje $7 D005762
650    _2
$a gastrointestinální látky $x terapeutické užití $7 D005765
650    _2
$a dodržování směrnic $x statistika a číselné údaje $7 D019983
650    _2
$a průzkumy zdravotní péče $7 D019538
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x terapeutické užití $7 D007155
650    _2
$a idiopatické střevní záněty $x diagnóza $x terapie $7 D015212
650    _2
$a infliximab $x terapeutické užití $7 D000069285
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a pediatrie $x metody $x normy $x statistika a číselné údaje $7 D010372
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a lékařská praxe - způsoby provádění $x statistika a číselné údaje $7 D010818
651    _2
$a Kanada $7 D002170
651    _2
$a Německo $7 D005858
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a de Ridder, Lissy $u Department of Paediatric Gastroenterology, The Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Ruemmele, Frank M $u Department of Paediatric Gastroenterology, Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Paris, France.
700    1_
$a Griffiths, Anne $u Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Buderus, Stephan $u Department of Paediatrics, St. Marien Hospital, Bonn, Germany.
700    1_
$a Hradsky, Ondrej $u Department of Paediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Hauer, Almuthe Christina $u GPGE-Educational Center for Paediatric Gastroenterology, Department of Paediatrics, Medical University of Graz, Graz, Austria.
773    0_
$w MED00010080 $t Journal of pediatric gastroenterology and nutrition $x 1536-4801 $g Roč. 68, č. 5 (2019), s. 676-683
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30664566 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155516 $b ABA008
999    __
$a ok $b bmc $g 1600026 $s 1116567
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 68 $c 5 $d 676-683 $e - $i 1536-4801 $m Journal of pediatric gastroenterology and nutrition $n J Pediatr Gastroenterol Nutr $x MED00010080
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...